Additionally, the 36-month beta value for APLT is 1.79. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for APLT is 86.61M and currently, short sellers hold a 20.96% ratio of that float. The average trading volume of APLT on December 30, 2024 was 5.30M shares.
APLT) stock’s latest price update
Applied Therapeutics Inc (NASDAQ: APLT)’s stock price has gone decline by -7.90 in comparison to its previous close of 0.85, however, the company has experienced a -10.70% decrease in its stock price over the last five trading days. accesswire.com reported 2024-12-30 that NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=119449&wire=1 or contact Joseph E. Levi, Esq.
APLT’s Market Performance
Applied Therapeutics Inc (APLT) has seen a -10.70% fall in stock performance for the week, with a -90.83% decline in the past month and a -90.75% plunge in the past quarter. The volatility ratio for the week is 12.94%, and the volatility levels for the past 30 days are at 14.79% for APLT. The simple moving average for the last 20 days is -31.19% for APLT’s stock, with a simple moving average of -86.23% for the last 200 days.
Analysts’ Opinion of APLT
UBS, on the other hand, stated in their research note that they expect to see APLT reach a price target of $2, previously predicting the price at $13. The rating they have provided for APLT stocks is “Neutral” according to the report published on December 02nd, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to APLT, setting the target price at $4 in the report published on November 29th of the current year.
APLT Trading at -86.52% from the 50-Day Moving Average
After a stumble in the market that brought APLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.60% of loss for the given period.
Volatility was left at 14.79%, however, over the last 30 days, the volatility rate increased by 12.94%, as shares sank -61.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -90.83% lower at present.
During the last 5 trading sessions, APLT fell by -10.09%, which changed the moving average for the period of 200-days by -86.40% in comparison to the 20-day moving average, which settled at $1.1425. In addition, Applied Therapeutics Inc saw -76.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLT starting from Funtleyder Leslie D., who sale 13,530 shares at the price of $5.83 back on Aug 22 ’24. After this action, Funtleyder Leslie D. now owns 277,911 shares of Applied Therapeutics Inc, valued at $78,880 using the latest closing price.
Perfetti Riccardo, the Chief Medical Officer of Applied Therapeutics Inc, sale 22,681 shares at $5.83 during a trade that took place back on Aug 22 ’24, which means that Perfetti Riccardo is holding 986,853 shares at $132,230 based on the most recent closing price.
Stock Fundamentals for APLT
Current profitability levels for the company are sitting at:
- 437.36 for the present operating margin
- 3.79 for the gross margin
The net margin for Applied Therapeutics Inc stands at 887.73. The total capital return value is set at -12.14.
Currently, EBITDA for the company is -64.53 million with net debt to EBITDA at 1.05. When we switch over and look at the enterprise to sales, we see a ratio of 17.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.06.
Conclusion
In conclusion, Applied Therapeutics Inc (APLT) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
